- Home
- SER vs RLYB Comparison
SER vs RLYB Comparison
Compare SER & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- RLYB
- Stock Information
- Founded
- SER 2017
- RLYB 2018
- Country
- SER United States
- RLYB United States
- Employees
- SER N/A
- RLYB N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- RLYB Health Care
- Exchange
- SER Nasdaq
- RLYB Nasdaq
- Market Cap
- SER 45.2M
- RLYB 42.7M
- IPO Year
- SER 2018
- RLYB 2021
- Fundamental
- Price
- SER $4.81
- RLYB $0.88
- Analyst Decision
- SER
- RLYB Buy
- Analyst Count
- SER 0
- RLYB 6
- Target Price
- SER N/A
- RLYB $8.10
- AVG Volume (30 Days)
- SER 31.9K
- RLYB 94.1K
- Earning Date
- SER 11-12-2024
- RLYB 03-11-2025
- Dividend Yield
- SER N/A
- RLYB N/A
- EPS Growth
- SER N/A
- RLYB N/A
- EPS
- SER N/A
- RLYB N/A
- Revenue
- SER $3,157,500.00
- RLYB $598,000.00
- Revenue This Year
- SER N/A
- RLYB N/A
- Revenue Next Year
- SER N/A
- RLYB N/A
- P/E Ratio
- SER N/A
- RLYB N/A
- Revenue Growth
- SER 2454.55
- RLYB N/A
- 52 Week Low
- SER $3.81
- RLYB $0.84
- 52 Week High
- SER $19.93
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- SER 46.26
- RLYB 37.61
- Support Level
- SER $4.70
- RLYB $0.89
- Resistance Level
- SER $5.40
- RLYB $0.95
- Average True Range (ATR)
- SER 0.49
- RLYB 0.07
- MACD
- SER -0.01
- RLYB -0.01
- Stochastic Oscillator
- SER 11.93
- RLYB 4.74
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.